

Probiotics for Dentistry

Ayşegül Mendi*

Faculty of Dentistry Department of Medical Microbiology, Gazi University, Turkey

*Corresponding Author: Ayşegül Mendi, Faculty of Dentistry Department of Medical Microbiology, Gazi University, Turkey.

Received: February 01, 2017; **Published:** March 01, 2017

The term probiotic –“for life”- is used with different meanings, but today two main definitions are used. According to FAO/WHO Report (2002), probiotics are “Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host” [1]. International Life Science Institute (ILSI) Europe suggests a definition according to which a probiotic is “a live microbial food ingredient that, when ingested in sufficient quantities, exerts health benefits on the consumer [2]. The most commonly used probiotic bacterial strains belong to the group of lactic acid bacteria, especially *Lactobacilli*, or to the genus *Bifidobacterium* [3]. In addition to bacteria, yeast and even helminths are used as probiotics [4].

The International Dairy Federation has published a bulletin summarizing the evidence for the effect of probiotic cultures on a range of diseases and disorders in humans. The bulletin No 380/2003 contains a section reviewing the evidence for clinical effects in an extensive range of conditions including lactose maldigestion, diarrhoea, immune modulation, inflammatory bowel syndrome, constipation, necrotising enterocolitis, *Helicobacter pylori* infection, small bacteria overgrowth, colorectal cancer, breast cancer, allergy, serum cholesterol and blood pressure decreasing, coronary heart disease, urinary tract infection, upper respiratory tract and related infections. Thereby probiotics have multiple mechanisms of action [5], including prevention of pathogenic bacterial growth, binding to or penetration of pathogens to mucosal surfaces, stimulation of mucosal barrier function, production of antimicrobial agents or altering immunoregulation, decreasing proinflammatory cytokines [3].

Importantly, it was shown that one of the primary metabolic products of probiotics, called exopolysaccharides (EPSs) have recently received an increasing amount of attention because of their technological application in dairy products and their potentially beneficial properties for human health. Most of EPS-producing LAB have been isolated from fermented foods. Recently gut microbiota from animals and humans is the microenvironment where EPSs producing LAB are isolated. It is obvious that LAB strains from different ecological niches are able to produce EPSs, but the physiological role of these polymers play in producing bacteria still remains unclear. EPSs have been suggested that they have a role in the recognition of different ecosystems and also that they have a protective function against detrimental environmental factors [6]. EPSs may be a good tool to explain the mechanism of action of probiotics.

Probiotics were suggested to play a role in maintaining oral health recently. Hereunder, there is a need to define therapeutics that focus on the diminution of dental plaque, the reduction of number of pathogens and the modulation of host immune response by controlling the release of inflammatory cytokines for periodontal diseases. On the basis of their therapeutic role in inflammatory bowel diseases and allergic disorders, probiotics may participate in the management and/or prevention of periodontal diseases by the induction of an immunomodulatory effect. LAB, as probiotics, are novel unitary agents that are widely utilized for their therapeutic activity. Nevertheless, this attack is still an emerging idea and there is insufficient scientific evidence to back its clinical role in oral health [7]. Our team suggest that if probiotics could restore the composition of the gut microbiome and introduce beneficial functions to gut microbial communities, resulting in amelioration or prevention of gut inflammation and other intestinal or systemic disease phenotypes, they can exert the same functional properties in the oral microbiome also. Abrogation of oral pathogens especially, *P. gingivalis* by *Lactobacilli* could be an advantage to prevent the development of periodontitis and/or other oral diseases. Lactic acid bacteria could compete with oral pathogens for adhesion to surface of cells for nutrition and as a consequence secretion of immunomodulatory cytokines from stromal cells and/or epithelial cells.

Given the widespread emergence of bacterial resistance to antibiotics, the concept of probiotic therapy has been considered for application in oral health. Dental caries, periodontal disease, and halitosis are among the oral disorders that have been targeted in clinical trials [8]. However, only a few studies are available on the prevalence, role, and effects of probiotic bacteria in the mouth. A Russian study examined probiotic tablets in a complex treatment of gingivitis and different degrees of periodontitis [9]. The treatment of the patients of the control group was provided by the drug Tantum Verde (Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Rome). The effect of probiotics on the normalization of microflora was found to be higher in comparison with Tantum Verde, particularly in the cases of gingivitis and periodontitis. Nase, *et al.* (2001) reported reduced tooth decay incidence in children taking probiotic *L. rhamnosus* GG-enriched milk versus a control group of children taking milk without probiotic enrichment [7]. Studies on periodontitis and gingivitis show differing results depending on the strains. For example, *Lactobacillus reuteri* can be used to reduce gingivitis and dental plaque in patients with moderate to severe gingivitis and also to reduce proinflammatory cytokine in gingival crevicular fluid [10]. On the other hand, *Lactobacillus salivarius* WB21 in tablets does not reduce the direct count of any specific periodontopathic bacteria-*Porphyromonas gingivalis*, *Prevotella intermedia*, *Tannerella forsythia*, *Treponema denticola* and *Aggregatibacter actinomycetemcomitans* [11], (even though this probiotic improves periodontal clinical parameters (probing pocket depth, gingival index, bleeding on probing and plaque index) especially in smoker subjects [12]. Commercially available probiotics that contain *Lactobacilli* species interfere with the *in vitro* ability of *Candida albicans* to form biofilms on dentures [13], yet conventional approve intestinal probiotics surprisingly have no oral persistence and any oral cavity health benefits seem transitory. These conflicting results point out that not all the probiotics have beneficial effects on periodontal diseases. Therefore, it seems necessary that to perform specific screenings for selecting appropriate probiotic strains for preventing gingivitis or periodontitis and other oral health diseases. Sookhee, *et al.* (2001) verified this hypothesis by investigating 130 volunteers in Thailand and found 3790 lactic acid bacterial strains from healthy oral cavities [14]. Of these, only five species expressed the inhibitory effect against other organisms, including oral *Candida*. The authors reported that the antimicrobial potentials of the bacteria were affected by several factors, such as pH, catalase, proteolytic enzymes, and temperature. Also it cannot be assumed that research published on one strain of probiotic applies to another strain, even of the same species. The key point is to realize that all probiotics do not have the same efficacy [15,16]. It is important that probiotic strains should be well characterized before and comprehensive *in vitro* research studies should be conducted.

Several requirements have been proposed for novel probiotic strains [1]. Isolates from healthy humans are advised and their functional properties and safety should be assessed by *in vitro* tests [17]. It has been shown that good antimicrobial properties of probiotic strains are necessary to eradicate or inhibit pathogenic bacteria. At the same time, significant fermentation type-, species-, and strain specific variability in functional probiotic properties of *lactobacilli*, such as antimicrobial activity as well as acid and bile tolerance of *lactobacilli*, has been observed [17]. Therefore several strains from various fermentation types and species should be tested to choose the best, those with high antimicrobial activity and high tolerance of environmental stress. Furthermore, one of the important issues is the safety of probiotics strains. There is growing concern about the development of antibiotic resistance in pathogenic microorganisms. The spread of antibiotic-resistance genes between bacterial species through lateral gene transfer may occur [18] and therefore, knowledge of the resistance pattern of the probiotic strains would be useful to avoid inducing strains that carry transferable genes.

As shown in Table 1 there are topics which should be explained by researchers. Since most of the functions ascribed to EPSs are of a protective nature. The ability of a microorganism to surround itself with a highly hydrated exopolysaccharide layer may provide it with protection against desiccation and predation. It is suggested that in terms of oral environment in clinical studies considering the stressful conditions created by saliva and teeth surface, high EPSs productive strains, may survive better (*in vivo* environment would be different from controlled *in vitro* conditions).

Studies in dental clinics with probiotics are characterized by a high level of heterogeneity due to the different behaviour of oral hygiene of human. Furthermore there is no sufficient *in vitro* models regarding probiotic effect. On the other hand Ibnou-Zekri, *et al.* (2003) highlighted that the activity of probiotic strains *in vitro* may not parallel similar *in vivo* behaviour [19].

Benefit	Function	Proposed mechanism
Digestive comfort	Irritable bowel syndrome, symptoms affecting the gastrointestinal tract in general (constipation, non-pathogeni diarrhea, distension, flatulance, cramp)	Change in populations or activities of the general intestinal microflora
	Lactose intolerance	Delivery of microbial lactase to small intestine
Defense	Allergy (atopical enzyme, allergy to the milk, rheumatoid arthritis)	Translocation, barrier effect
	Carcinogenicity, mutagenicity, tumor	Absorption of the mutagen, stimulation of the immune system, inhibition of carcinogen production by the intestinal microflora
	Diarrhea linked to antibiotics, diarrhea caused by Rotavirus, colitis caused by <i>C. difficile</i> , nosocomial diarrhea	Competitive exclusion, translocation/barrier effect, immune response promoted
	<i>Helicobacter pylori</i>	Antipathogenic activity
	Immunomodulation (immune status, vaccinal response)	Interaction with the immune cells or cell receptors leading to an increase in the phagocytic activity of white cells, increasing IgA levels after exposure to the antigen, increasing the proliferation of the intra-epithelial leukocytes, regulating the Th1/Th2 ratio, induction of cytokine synthesis
	Excessive intestine bacterial growth	Antimicrobial activity, competitive exclusion
Oral diseases		EPS production, biofilm inhibition, antioxidative activity, competitive adhesion, immunomodulatory effect

Table 1: The probiotic effects reported and their putative mechanisms.

To determine further the role of probiotics in the dentistry, large, well designed, multicenter controlled clinical trials are needed. The fact that not all *lactobacillus* and *bifidobacterim* species are equally beneficial should not be discarded. Individual mechanism of each strains should be characterised and the researchers should be aware of that the action of mechanism is dependent on the host characteristics such as oral hygiene, and nutrition habit.

Functional properties of probiotic strains are different among the strains and they do not show the same health benefit efficacy. Therefore strains isolated from gut microflora could not give the same results in oral microbiome. Researchers should set their goal in identifying strains from oral microbiome. Selecting the new oral probiotic strains should be focused on the diminution of dental plaque, the reduction of the number of periodontal pathogens and the modulation of the host immune response by controlling the release of inflammatory cytokines, which may slow down the destruction of supporting tissues. Probiotic strain- oral mucosal cell interactions should be investigated also.

Bibliography

1. FAO/WHO. "Guidelines for the Evaluation of Probiotics in Food. Report of a Joint Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food". London, Ontario, Canada (2002).
2. Ashwell M. "Concept of functional foods". ILSI Europe Concise Monograph series, Brussels, Belgium. International Life Sciences Institute (2002).

3. Saxelin M., *et al.* "Probiotic and other functional microbes: from markets to mechanisms". *Current Opinion in Biotechnology* 16.2 (2005): 204-211.
4. Summers RW., *et al.* "Trichuris suis therapy in Crohn's disease". *Gut* 54.1 (2005): 87-90.
5. Toma MM and Pokrotnieks J. "Probiotics as functional food microbiological and medical aspects". *Acta Universitatis Latviensis* 710 (2006): 117-129.
6. Ruas-Madiedo P., *et al.* "Screening of exopolysaccharide-producing Lactobacillus. and Bifidobacterium strains isolated from the human intestinal microbiota". *Applied and Environmental Microbiology* 73.13 (2007): 4385-4388.
7. Nasae L., *et al.* "Effect of long term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG in milk on dental caries and caries risk in children". *Caries Research* 35.6 (2001): 412-420.
8. Meurman JH. "Probiotics: Do they have a role in oral medicine and dentistry?" *European Journal of Oral Sciences* 113.3 (2005): 188-196.
9. Grudianov AI., *et al.* "Use of probiotics Bifidumbacterin and Acilact in tablets in therapy of periodontal inflammations". *Stomatologiya (Mosk)* 81.1 (2002): 39-43.
10. Krasse P., *et al.* "Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri". *Swedish Dental Journal* 30.2 (2006): 55-60.
11. Mayanagi G., *et al.* "Probiotic effects of orally administered Lactobacillus salivarius WB21-containing tablets on periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial". *Journal of Clinical Periodontology* 36.6 (2009): 506-513.
12. Shimauchi H., *et al.* "Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, double-blind, placebo-controlled study". *Journal of Clinical Periodontology* 35.10 (2008): 897-899.
13. Uiaoney S., *et al.* "In vitro effect of over-the-counter probiotics on the ability of Candida albicans to form biofilm on denture strips". *Journal of Dental Hygiene* 88.3 (2014): 183-189.
14. Sokhee S., *et al.* "Lactic acid bacteria from healthy oral cavity of Thai volunteers: inhibition of oral pathogens". *Journal of Applied Microbiology* 90.2 (2001):172-179.
15. Lee YK and Salminen S. "The coming of age of probiotics". *Trends in Food Science and Technology* 6 (1995): 241-245.
16. Tuomola E., *et al.* "Quality assurance criteria for probiotic bacteria". *American Journal of Clinical Nutrition* 73.2 (2001): 393S-398S.
17. Saarela M., *et al.* "Probiotic bacteria: safety, functional and technological properties". *Journal of Biotechnology* 84.3 (2000): 197-215.
18. Duncan MJ. "Genomics of oral bacteria". *Critical Reviews in Oral Biology and Medicine* 14.3 (2003): 175-187.
19. Ibnou-Zekri N., *et al.* "Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro". *Infection and Immunity* 71.1 (2003): 428-436.

Volume 6 Issue 4 March 2017

© All rights reserved by Ayşegül Mendi.